

2021/02

20 February 2021

PHARMAC
PO Box 10254
The Terrace
WELLINGTON 6143

By email: consult@pharmac.govt.nz

Tēnā koe

Proposal to widen access to Secukinumab (Cosentyx) for psoriatic and ankylosing spondylitis

Tōpūtanga Tapuhi Kaitiaki o Aotearoa, New Zealand Nurses Organisation (NZNO) welcomes the opportunity to comment on a proposal to widen access to Secukinumab (Cosentyx) for psoriatic and ankylosing spondylitis.

NZNO is the leading professional nursing association and union for nurses in Aotearoa New Zealand, representing 51,000 nurses, midwives, students, kaimahi hauora and health workers on professional and employment matters. NZNO embraces Te Tiriti o Waitangi and contributes to the improvements of the health status and outcomes of all people of Aotearoa New Zealand through influencing health, employment, and social policy development.

Furthermore, we share the intent of the Ministry of Health's definition of equity which equally applies to NZNO work across professional, industrial and member activities.

NZNO supports PHARMAC's proposal to widen access to secukinumab (Cosentyx) so that Secukinumab will be funded as a first line biologic for psoriatic arthritis and a second line biologic for ankylosing spondylitis.

Thank you for the opportunity to participate in the consultation process

Nāku noa nā



Lucia Bercinskas
Senior Policy Analyst
(04) 912 1099